Northern Trust Corp Inmune Bio, Inc. Transaction History

Northern Trust Corp

$690 Billion
Q4 2024

A detailed history of Northern Trust Corp transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 105,961 shares of INMB stock, worth $910,204. This represents 0.0% of its overall portfolio holdings.

Number of Shares

105,961

Previous 96,807 9.46%

Holding current value

$910,204

Previous $521,000 5.18%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$4.4 - $6.43 $40,277 - $58,860	9,154 Added 9.46%	105,961 $494,000
Q3 2024 Nov 13, 2024	BUY	$4.86 - $9.86 $334,115 - $677,855	68,748 Added 245.01%	96,807 $521,000
Q2 2024 Aug 14, 2024	BUY	$7.15 - $11.84 $54,640 - $90,481	7,642 Added 37.43%	28,059 $247,000
Q1 2024 May 14, 2024	SELL	$10.53 - $14.01 $48,985 - $65,174	-4,652 Reduced 18.56%	20,417 $239,000
Q4 2023 Feb 13, 2024	BUY	$6.6 - $11.52 $31,673 - $55,284	4,799 Added 23.68%	25,069 $282,000
Q2 2023 Aug 11, 2023	SELL	$6.5 - $10.09 $175 - $272	-27 Reduced 0.13%	20,270 $184,000
Q1 2023 May 15, 2023	BUY	$6.01 - $10.18 $7,157 - $12,124	1,191 Added 6.23%	20,297 $131,000
Q2 2022 Aug 12, 2022	SELL	$5.48 - $8.97 $4,378 - $7,167	-799 Reduced 4.01%	19,106 $169,000
Q4 2021 Feb 08, 2022	SELL	$9.97 - $20.38 $23,090 - $47,200	-2,316 Reduced 10.42%	19,905 $203,000
Q3 2021 Nov 15, 2021	BUY	$14.13 - $27.85 $116,883 - $230,375	8,272 Added 59.3%	22,221 $432,000
Q1 2021 May 12, 2021	BUY	$11.61 - $26.85 $18,285 - $42,288	1,575 Added 12.73%	13,949 $166,000
Q4 2020 Feb 11, 2021	BUY	$7.51 - $17.22 $92,928 - $213,080	12,374 New	12,374 $213,000

Others Institutions Holding INMB

# of Institutions

Shares Held

7.04M

Call Options Held

202K

Put Options Held

42.9K

View Full List

About Inmune Bio, Inc.

Ticker INMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,946,000
Market Cap $154M
Description
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...

More about INMB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Inmune Bio, Inc. Transaction History